Epalrestat is indicated for the improvement of subjective symptoms (numbness and pain), abnormality of vibration sense, and abnormal change in heartbeat associated with diabetic peripheral neuropathy (when high glycohemoglobin value is noted).
Epalrestat
Generic MedicinePharmacology
Epalrestat specifically inhibits aldose reductase and accumulation of sorbitol in the nerve, thereby improving subjective symptoms and nerve dysfunction in patients with diabetic peripheral neuropathy.
Dosage Administration
The usual adult dose is 1 tablet (50 mg) three times daily before each meal. The dosage may be adjusted according to the patient's age and symptoms.
Interactions
There are no known drug interactions and none well documented.
Contraindications
The drug is contraindicated for patients with known hypersensitivity to epalrestat.
Side Effects
Major adverse reactions are hepatic function abnormalities and thrombocytopenia. In cases of hepatic abnormalities, the drug should be discontinued immediately and appropriate measures should be taken. Other reactions may include malaise, headache, abdominal pain, nausea, and hypersensitivity reaction, etc.
Pregnancy & Lactation
The safety of epalrestat in pregnant women has not been established. The drug may be used in pregnant women or in women who may possibly be pregnant only if expected therapeutic benefits outweigh the possible risks associated with the treatment. Breastfeeding should be avoided during administration of epalrestat
Precautions & Warnings
The administration of epalrestat should be considered for patients showing high glycohemoglobin values even after fundamental therapies for diabetes mellitus such as diet therapy, exercise therapy, and treatment with an oral hypoglycemic agent, insulin, etc. The efficacy of this product has not been established in patients with diabetic peripheral neuropathy with irreversible organic changes. The patient should be carefully monitored during the administration of this product. When the efficacy of this product is not observed even after 12 weeks of administration, other appropriate therapies should be taken.
Therapeutic Class
Aldose reductase inhibitor
Storage Conditions
Do not store above 30°C temperature. Keep away from light and wet place. Keep out of reach of children.
Common Questions
What is Epalrestat for?
What does Epalrestat do?
What are the side effects of Epalrestat?
What happens if you take too much Epalrestat?
Can Epalrestat be taken during pregnancy?
No available drugs found